CSL will pay an upfront US$355 million ($515m) to co-develop an external drug candidate aimed at treating rare kidney and ...

CSL ( CSLLY) agreed to pay Alentis Therapeutics $355 million upfront as part of a global partnership to develop lixudebart, ...

Pathalys Pharma, Inc., a private, US-based biopharmaceutical company committed to supporting the unique needs of patients with chronic kidney disease (CKD), announced today that data from the ...

Chronic kidney disease often develops without obvious symptoms, but your body may show important warning signs long before ...

I have summarized the "pathology," "treatment," and "side effects of medication."Pathology• Cyst cells proliferate abnormally ...

Add Yahoo as a preferred source to see more of our stories on Google. Testing for kidney function can help identify chronic kidney disease early enough to intervene. PIXOLOGICSTUDIO/Science Photo ...

Over 95,000 Americans need a new kidney, but early organ failure often shows no signs before it suddenly turns into a ...

Chronic kidney disease (CKD) is the progressive and irreversible loss of kidney function. This affects essential bodily functions, including mineral balance, red blood cell production, and waste ...

By Rajasik Mukherjee Oct 5 (Reuters) - Australia's CSL said on Monday it had entered into an agreement with Swiss drugmaker Alentis Therapeutics to co-develop and co-promote a treatment for rare ...

Presentations include real-world XPHOZAH® (tenapanor) data and new insights into hyperphosphatemia management and outcomes.

Chronic kidney disease of unknown origin (CKDu) is an ongoing global health concern and public health challenge. Often ...